SUPRIYA

Supriya Lifescience Share Price

₹729.80 -34.85 (-4.56%)

21 Dec, 2024 18:07

SIP TrendupStart SIP in SUPRIYA

Start SIP

Performance

  • Low
  • ₹723
  • High
  • ₹783
  • 52 Week Low
  • ₹270
  • 52 Week High
  • ₹835
  • Open Price₹764
  • Previous Close₹765
  • Volume357,085

Investment Returns

  • Over 1 Month + 5.71%
  • Over 3 Month + 15.65%
  • Over 6 Month + 84.55%
  • Over 1 Year + 168.11%
SIP Lightning

Smart Investing Starts Here Start SIP with Supriya Lifescience for Steady Growth!

Invest Now

Supriya Lifescience Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 37.3
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 5,874
  • P/B Ratio
  • 7.2
  • Average True Range
  • 37.82
  • EPS
  • 19.57
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 26
  • RSI
  • 49.58
  • MFI
  • 59.26

Supriya Lifescience Financials

Supriya Lifescience Technicals

EMA & SMA

Current Price
₹729.80
-34.85 (-4.56%)
pointer
  • stock-down_img
  • Bullish Moving Average 7
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹742.96
  • 50 Day
  • ₹691.54
  • 100 Day
  • ₹620.34
  • 200 Day
  • ₹528.65

Resistance and Support

745.2 Pivot Speed
  • R3 828.55
  • R2 805.90
  • R1 767.85
  • S1 707.15
  • S2 684.50
  • S3 646.45

What's your outlook on Supriya Lifescience?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Supriya Lifescience is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) with over 38 APIs across various therapeutic segments. It exports to 86 countries, supplying high-quality APIs for pharmaceuticals, nutraceuticals, and personal care industries.

Supriya Lifescience has an operating revenue of Rs. 624.98 Cr. on a trailing 12-month basis. An annual revenue growth of 24% is outstanding, Pre-tax margin of 29% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 55% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 13% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 90 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Supplies and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Supriya Lifescience Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-08-10 Quarterly Results
2024-05-28 Audited Results & Final Dividend
2024-02-07 Quarterly Results
2023-11-07 Quarterly Results

Supriya Lifescience F&O

Supriya Lifescience Shareholding Pattern

68.3%
0.62%
3.23%
6.03%
0%
21.82%

About Supriya Lifescience

  • NSE Symbol
  • SUPRIYA
  • BSE Symbol
  • 543434
  • ISIN
  • INE07RO01027

Similar Stocks to Supriya Lifescience

Supriya Lifescience FAQs

Supriya Lifescience share price is ₹729 As on 21 December, 2024 | 17:53

The Market Cap of Supriya Lifescience is ₹5873.6 Cr As on 21 December, 2024 | 17:53

The P/E ratio of Supriya Lifescience is 37.3 As on 21 December, 2024 | 17:53

The PB ratio of Supriya Lifescience is 7.2 As on 21 December, 2024 | 17:53

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23